Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 2.156 Facteur d'impact sur 5 ans: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v22.i4.50
pages 309-324

Integrin Control of Tumor Invasion

Dara S. Missan
Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York, USA
Michael DiPersio
Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York, USA

RÉSUMÉ

Metastasis is the leading cause of death in cancer patients, and strategies to inhibit tumor cell invasion are a major focus of current efforts to develop cancer treatments. The extracellular matrix (ECM) provides both structural support and extracellular cues that regulate invasive tumor growth, and tumor-associated changes in ECM contribute to cancer progression. Integrins, the major receptors for cell adhesion to ECM, are important at every stage of cancer and occupy a critical position as transducers of chemical and mechanical signals that control tumor cell responses to ECM (i.e., outside-in signaling), as well as tumor-mediated changes to ECM that facilitate invasive growth and metastasis (i.e., inside-out signaling). Integrins are therefore attractive therapeutic targets for antagonistic agents. Here, we provide an overview of cancer-promoting functions of integrins on tumor cells, with a focus on roles in regulating cell invasion, ECM remodeling, tumor angiogenesis, and gene expression. We will also discuss how integrin functions are modulated by ECM ligands outside the cell, cytoskeletal/signaling proteins inside the cell, and other cell surface proteins. Finally, we will discuss current progress towards developing integrin antagonists for clinical use, including barriers that must still be overcome before integrins can be fully exploited as therapeutic targets.


Articles with similar content:

Targeting Integrins in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Chiara Pazzagli, Sandra Donnini
Resistance to Cell Death and Its Modulation in Cancer Stem Cells
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Ahmad R. Safa
Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Peng Li, Ruocong Zhao, Yunxin Lai
Role of NF-κB in Tumorigenesis
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 2
Gautam Sethi, Muthu K. Shanmugam, Alan P. Kumar, Benny K. H. Tan
Anoikis and EMT: Lethal "Liaisons" during Cancer Progression
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Natasha Kyprianou, Zheng Cao, Theodore Livas